Contrary to recent social media posts, GLP-1 drugs are not shredding away people's bones.
New research reaffirms that GLP-1s can help prevent heart attacks, but only as long as you're taking them.
Eli Lilly has issued a new warning against buying compounded versions of its drug tirzepatide, claiming to have found potentially dangerous impurities.
Over a 24 week period, people on UBT251 lost up to 20% of their body weight on average.
The lawsuit is the latest in an escalating feud between the Danish pharmaceutical and telehealth company.
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo.
Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose some weight.
People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.
People taking an obesity drug typically regain weight, a new review finds, often even quicker than people who lose weight through lifestyle changes alone.
It's the first GLP-1 pill approved for treating obesity.
New research finds that people taking GLP-1 tend to spend less money grocery shopping, especially on snacks.
People who switched from semaglutide or tirzepatide to orforglipron largely maintained their weight loss.
Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
In an early human trial, Eli Lilly's eloralintide helped people lose up to 20% of their body weight.
New research suggests that people taking GLP-1 therapy are less likely to die from colorectal cancer.
New research continues to show that many people meet the criteria for obesity and associated health problems, even if their BMI looks fine.
Severe diverticulitis is becoming a bigger issue for people under 50.
New research finds that the reported rise in many cancers isn't just limited to younger adults.
New research shows that substantially more Americans would qualify as being obese using new diagnostic criteria released this year.
The study, published last year, was found to contain unreliable and "implausible" data.
